Tokyo Tape
Sign in
← PeptiDream

Annual report

4587.TEDINET S100XRP4
Period2025-01-01 → 2025-12-31
Filed2026-03-18
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 152
MetricValuePeriodScopeSource row
Revenue¥18.5bn2025-01-01 → 2025-12-31Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31vCons.Revenue IFRS (5-year summary)
Revenue¥26.9bn2022-01-01 → 2022-12-31vCons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2021-01-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Operating income−¥5.0bn2025-01-01 → 2025-12-31Cons.Operating profit loss IFRS
Operating income¥21.1bn2024-01-01 → 2024-12-31Cons.Operating profit loss IFRS
Profit before tax−¥5.3bn2025-01-01 → 2025-12-31Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥6.7bn2022-01-01 → 2022-12-31vCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-12-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31vCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income−¥3.7bn2025-01-01 → 2025-12-31Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS
Total assets¥77.0bnat 2025-12-31Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31vCons.Total assets IFRS (5-year summary)
Total assets¥63.9bnat 2022-12-31vCons.Total assets IFRS (5-year summary)
Total assets¥27.0bnat 2021-12-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥25.5bnat 2025-12-31Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥51.5bnat 2025-12-31Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥51.5bnat 2025-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥32.0bnat 2022-12-31vCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥25.4bnat 2021-12-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥28.7bnat 2025-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31vCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow−¥13.3bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥83m2022-01-01 → 2022-12-31vCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥2.1bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31vCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥4.1bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31vCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥66m2021-01-01 → 2021-12-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥-28.992025-01-01 → 2025-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥58.192022-01-01 → 2022-12-31vCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.962021-01-01 → 2021-12-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-28.992025-01-01 → 2025-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥58.142022-01-01 → 2022-12-31vCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.812021-01-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥398.53at 2025-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥437.63at 2024-12-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥311.16at 2023-12-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥246.63at 2022-12-31vCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥195.1at 2021-12-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio66.9%at 2025-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31vCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE-6.9%2025-01-01 → 2025-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE30.9%2024-01-01 → 2024-12-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2023-01-01 → 2023-12-31vCons.Rate of return on equity IFRS (5-year summary)
ROE26.3%2022-01-01 → 2022-12-31vCons.Rate of return on equity IFRS (5-year summary)
ROE11.0%2021-01-01 → 2021-12-31dCons.Rate of return on equity IFRS (5-year summary)
Employees645at 2025-12-31Cons.Number of employees
Employees621at 2024-12-31Cons.Number of employees
Employees603at 2023-12-31vCons.Number of employees
Employees569at 2022-12-31vCons.Number of employees
Employees141at 2021-12-31dCons.Number of employees
Revenue¥2.8bn2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥31.3bn2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥12.7bn2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥15.4bn2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥9.4bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥5.3bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income¥21.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥5.3bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income¥20.5bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income¥6.4bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥8.8bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥4.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥6.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax¥29.8bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥5.4bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income¥21.1bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income¥5.8bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income¥4.3bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income¥3.6bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥70.1bnat 2025-12-31StandaloneAssets
Total assets¥89.7bnat 2024-12-31StandaloneAssets
Total assets¥68.2bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥55.2bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥26.6bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥20.7bnat 2025-12-31StandaloneLiabilities
Total liabilities¥34.1bnat 2024-12-31StandaloneLiabilities
Net assets / equity¥49.4bnat 2025-12-31StandaloneNet assets
Net assets / equity¥55.6bnat 2024-12-31StandaloneNet assets
Net assets / equity¥40.6bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥29.4bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥25.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥24.3bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥44.6bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥11.7bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥66m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-41.932025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥162.62024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥44.852023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥33.112022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥27.982021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥27.782021-01-01 → 2021-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥381.72at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥428.73at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥312.89at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥226.48at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥192.39at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio70.4%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio62.0%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio59.5%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio53.2%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.8%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE-10.3%2025-01-01 → 2025-12-31StandaloneRate of return on equity (5-year summary)
ROE43.8%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE16.6%2023-01-01 → 2023-12-31vStandaloneRate of return on equity (5-year summary)
ROE15.8%2022-01-01 → 2022-12-31vStandaloneRate of return on equity (5-year summary)
ROE15.6%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued130,010,400at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued130,010,400at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees169at 2025-12-31StandaloneNumber of employees
Employees157at 2024-12-31StandaloneNumber of employees
Employees153at 2023-12-31vStandaloneNumber of employees
Employees155at 2022-12-31vStandaloneNumber of employees
Employees141at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-12-31−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-12-31−¥1.2bn
Drug Discovery And Development Businessreportable segmentemployeesat 2025-12-31169 pure
Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-12-31¥2.8bn
Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-12-31¥2.8bn
Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-12-31−¥5.4bn
Radiopharmaceuticals Businessreportable segmentemployeesat 2025-12-31476 pure
Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-12-31¥16.9bn
Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-12-31¥15.7bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-12-31¥1.2bn
Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-12-31¥435m
—segment totalrevenue2025-01-01 → 2025-12-31¥19.7bn
—segment totalrevenue external2025-01-01 → 2025-12-31¥18.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-12-31¥1.2bn
—segment totalsegment profit2025-01-01 → 2025-12-31−¥4.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-12-31−¥741m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-12-31−¥741m
Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥31.3bn
Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥31.3bn
Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-12-31¥21.0bn
Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥16.1bn
Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥15.4bn
Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-12-31¥741m
Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-12-31¥247m
—segment totalrevenue2024-01-01 → 2024-12-31¥47.4bn
—segment totalrevenue external2024-01-01 → 2024-12-31¥46.7bn
—segment totalrevenue intersegment2024-01-01 → 2024-12-31¥741m
—segment totalsegment profit2024-01-01 → 2024-12-31¥21.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,493
ItemContextValueUnit
Finance costs IFRSPrior1YearDuration658895000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YearDuration22615000JPY
Profit loss before tax IFRSPrior1YearDuration20888805000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember714970000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember1533501000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration_ReportableSegmentsMember2248471000JPY
Depreciation and amortization operating expenses IFRSPrior1YearDuration2248471000JPY
Revenue from external customers IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember2793300000JPY
Revenue from external customers IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember15727934000JPY
Revenue from external customers IFRSCurrentYearDuration_ReportableSegmentsMember18521234000JPY
Revenue from external customers IFRSCurrentYearDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYearDuration18521234000JPY
Intersegment revenue IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember1150964000JPY
Intersegment revenue IFRSCurrentYearDuration_ReportableSegmentsMember1150964000JPY
Intersegment revenue IFRSCurrentYearDuration_ReconcilingItemsMember-1150964000JPY
Intersegment revenue IFRSCurrentYearDuration－JPY
Revenue IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember2793300000JPY
Revenue IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember16878899000JPY
Revenue IFRSCurrentYearDuration_ReportableSegmentsMember19672199000JPY
Revenue IFRSCurrentYearDuration_ReconcilingItemsMember-1150964000JPY
Revenue IFRSCurrentYearDuration18521234000JPY
Segment profit loss IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-5357999000JPY
Segment profit loss IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember434803000JPY
Segment profit loss IFRSCurrentYearDuration_ReportableSegmentsMember-4923195000JPY
Segment profit loss IFRSCurrentYearDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSCurrentYearDuration-4923195000JPY
Business combination related expenses IFRSCurrentYearDuration90000000JPY
Operating profit loss IFRSCurrentYearDuration-5013195000JPY
Finance income IFRSCurrentYearDuration242609000JPY
Finance costs IFRSCurrentYearDuration500314000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYearDuration-41228000JPY
Profit loss before tax IFRSCurrentYearDuration-5312129000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember719697000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_jpcrp030000-asr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember1406812000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration_ReportableSegmentsMember2126510000JPY
Depreciation and amortization operating expenses IFRSCurrentYearDuration2126510000JPY
Merchandise and finished goods ca IFRSPrior1YearInstant452202000JPY
Merchandise and finished goods ca IFRSCurrentYearInstant598142000JPY
Raw materials and supplies ca IFRSPrior1YearInstant2219456000JPY
Raw materials and supplies ca IFRSCurrentYearInstant2592425000JPY
Inventories ca IFRSPrior1YearInstant2671658000JPY
Inventories ca IFRSCurrentYearInstant3190567000JPY
Land acquisition cost IFRSPrior1YearInstant5860819000JPY
Buildings and structures acquisition cost IFRSPrior1YearInstant9516468000JPY
Machinery and vehicles acquisition cost IFRSPrior1YearInstant2774626000JPY
Tools furniture and fixtures acquisition cost IFRSPrior1YearInstant5827411000JPY
Construction in progress acquisition cost IFRSPrior1YearInstant1173817000JPY
Right of use assets acquisition cost IFRSPrior1YearInstant923040000JPY
Property plant and equipment acquisition cost IFRSPrior1YearInstant26076184000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass